SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-124739
Filing Date
2023-12-08
Accepted
2023-12-08 16:56:26
Documents
13
Period of Report
2023-12-08
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2332527d1_8k.htm   iXBRL 8-K 25771
2 EXHIBIT 3.1 tm2332527d1_ex3-1.htm EX-3.1 8380
  Complete submission text file 0001104659-23-124739.txt   214338

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rnaz-20231208.xsd EX-101.SCH 3054
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rnaz-20231208_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rnaz-20231208_pre.xml EX-101.PRE 22385
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2332527d1_8k_htm.xml XML 3512
Mailing Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109
Business Address 6 LIBERTY SQUARE #2382 BOSTON MA 02109 857-301-6857
Transcode Therapeutics, Inc. (Filer) CIK: 0001829635 (see all company filings)

IRS No.: 811065054 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40363 | Film No.: 231476158
SIC: 2834 Pharmaceutical Preparations